Mirouse A, et al. - In this multicenter prospective open-label study, 30 individuals were examined to study the long term safety and effectiveness of ustekinumab therapy for Behcet's disease (BD) associated oral ulcers (OU) resistant to colchicine. As compared to baseline, the median number of OU per patient was significantly lower at week 12 of ustekinumab therapy. Significantly lower median Behcet's syndrome activity score (in which higher scores symbolizing a more active disease) was reported at week 12 and 24 when compared to baseline. They recorded BD flare and side effect as the causes for ustekinumab withdrawal. They considered ustekinumab effective in BD-related oral ulcers resistant to colchicine.